AcroCyte Therapeutics Awarded ARPA ‑H Funding to Advance Scalable Human Organoid Technologies
News July 23,2026
TAIPEI and SAN CARLOS, Calif., July 23, 2026 /PRNewswire/ -- AcroCyte Therapeutics Inc. announced today that it has been selected to receive funding from the Advanced Research Projects Agency for Health (ARPA‑H) to advance scalable human organoid technologies for regenerative medicine applications.

Established by the U.S. government in 2022, ARPA‑H was modeled after the Defense Advanced Research Projects Agency (DARPA) to support high‑risk, high‑reward research programs with the potential to transform human health. Rather than funding incremental advances, ARPA‑H focuses on enabling disruptive technologies capable of addressing major unmet medical and societal challenges.

Among ARPA‑H's priority focus areas is regenerative medicine, including flagship programs aimed at addressing the global shortage of transplantable organs through the development of bioengineered, clinically functional replacement tissues and organs. AcroCyte's selection reflects recognition of its original cell expansion technology as a critical enabling platform for these ambitious efforts.

Core Technology: R3CE® Platform Enables Standardized, Scalable Organoid Production

Human organoids represent one of the most promising frontiers in biomedical science; however, their translation into clinical and translational applications has been limited by long‑standing challenges, including scalability, reproducibility, and manufacturing standardization.

AcroCyte has addressed these challenges through its proprietary R3CE® (Rapid Reproducible Rare Cell 3D Expansion) platform, which enables highly reproducible and standardized three‑dimensional expansion of rare human cells. The R3CE® platform is currently FDA‑registered as a Class I medical device, making it the first standardized organoid expansion system to obtain this regulatory designation.

Using minimally invasive procedures, autologous kidney cells can be obtained from patients and expanded within weeks into physiologically relevant renal organoid modules. This capability supports new pathways for regenerative research and translational development beyond conventional organ transplantation.

International Clinical Strategy: Parallel Development in the U.S. and Taiwan

The ARPA‑H–supported project will be executed through a binational clinical and translational strategy, integrating clinical expertise in both the United States and Taiwan. AcroCyte will collaborate with the University of Chicago Medicine in the U.S. and National Taiwan University Hospital (NTUH), together with the National Center for Biomodels (NCB), to pursue parallel development efforts across both regions.

This coordinated approach is designed to support early alignment with international regulatory standards and facilitate efficient translation toward global clinical applications.

AcroCyte's CEO Statement

"Being selected for support by ARPA‑H is a strong validation of our team's long‑term commitment to advancing three‑dimensional cell technologies," said Dr. Ying C. Chang, Co‑Founder and Chief Executive Officer of AcroCyte Therapeutics. "Following our recognition at MEDICA 2025, where AcroCyte became the first biotechnology company from Taiwan to secure second place in the MEDICA Start-up Competition, this milestone underscores AcroCyte's role in advancing organoid technologies across borders. Our focus is on translating organoid platforms from the laboratory into standardized systems that support regenerative and translational medicine."

NTUH's Vice Superintendent Statement

"NTUH participation as a clinical partner alongside the University of Chicago Medicine in this ARPA-H project reflects international recognition of our clinical and research excellence in regenerative medicine," stated Professor Jia-Horng Kao, Vice Superintendent of NTUH. "Kidney disease remains a significant health concern in Taiwan. Through this collaboration, we hope to integrate global research resources and clinical expertise to advance regenerative medicine for patients with chronic kidney disease."

About AcroCyte Therapeutics Inc.

AcroCyte Therapeutics Inc. is a biotechnology company dedicated to addressing key challenges in New Approach Methodologies (NAMs) by enabling reproducible, robust, and scalable human‑relevant model systems. Through its organoid platforms, the company is advancing animal‑free, high‑throughput alternatives for drug discovery and safety assessment, while enhancing translational relevance across drug development and regenerative medicine.

AcroCyte maintains research and development operations in Silicon Valley, California, and continues to advance high‑quality, scalable cell‑based technologies toward global clinical use.

This research was funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the U.S. Government.
Back
Privacy Preference Center

1. Who We Are
At AcroCyte Therapeutics Inc. (“AcroCyte”, “we”, “our”), we are committed to maintaining the trust and confidence of all visitors to our website, www.acrocyte.com. We value your privacy and want you to be clear about how we handle your data. In particular, AcroCyte is not in the business of selling, renting, or trading email lists with other companies for marketing purposes. This Privacy Policy outlines when and why we collect personal information, how we use it, the limited conditions under which we may disclose it to others, and how we keep it secure.

2. Information We Collect & How We Use It
Contact Forms & Business Inquiries
When you contact us via the forms on our website (such as the "Contact Us" page), we collect the professional information you provide, including your name, email address, phone number, company name, job title, industry, area of interest, and the content of your inquiry.

  • Purpose: We use this data solely to communicate with you, verify your identity, answer your technical or business questions, and provide information about our products and services relevant to your request.
  • Marketing Communications: We will only send you newsletters, product updates, or promotional materials if you have explicitly opted in by checking the relevant box (e.g., "Yes, I'd like to receive updates about AcroCyte news and breakthroughs"). You may unsubscribe from these communications at any time by clicking the "unsubscribe" link in our emails.

Cookies
We use cookies to support essential website functionality and to provide a better user experience. You can choose to disable or delete cookies at any time through your internet browser settings; however, this may limit your ability to use certain features of our website.

3. Third-Party Services & Data Processors

Google Analytics
We use Google Analytics to collect standard internet log information and details of visitor behavior patterns. This helps us understand website traffic and improve performance. This information is processed in a way that does not identify anyone personally. We do not make, and do not allow Google to make, any attempt to find out the identities of those visiting our website.

Google reCAPTCHA
To protect our website forms from spam and automated abuse, we use the reCAPTCHA service provided by Google. This service analyzes behavior to distinguish between humans and bots. Your use of reCAPTCHA is subject to Google’s Privacy Policy and Terms of Service.

Service Providers
We may share your information with trusted third-party service providers who assist us in operating our website, conducting our business, or serving our users (e.g., email delivery services, CRM systems, or hosting providers), so long as those parties agree to keep this information confidential.

4. International Data Transfers
AcroCyte operates globally with offices in Taiwan and the United States. Please be aware that your personal information may be transferred to, stored, and processed in a country other than the one in which you reside. By providing us with your information, you acknowledge and agree to this transfer, storage, or processing. We take all reasonable steps to ensure that your data is treated securely and in accordance with this policy.

5. Data Retention
We retain your personal information only for as long as is necessary to fulfill the purposes for which it was collected, including for the purposes of satisfying any legal, accounting, or reporting requirements. When data is no longer needed, we will securely delete or anonymize it.

6. Access to Your Personal Information & Your Rights
You have the right to request access to, correction of, or deletion of any personal data that we hold about you. Depending on your jurisdiction (such as under the GDPR), you may also have the right to restrict processing, object to processing, or request data portability. To make such a request, please contact our Privacy Team at [info@acrocyte.com].

7. Changes to Our Privacy Policy
We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. The most current version will always be available on our website. By continuing to access or use our website after those changes become effective, you agree to be bound by the revised Privacy Policy.

Cookie Notice